Cingulate Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
35.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$2.9Mnext fiscal year
FY EPS (est.)
-$2.30next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly25.9MTarget: Sufficient to fund operations and pre-commercialization activities into 2027
Quarterly Net Loss Quarterly-9.3MTarget: Reduction post-commercialization of lead assets
Quarterly Cash Burn (Operating Cash Flow) Quarterly-7MTarget: Stabilization during regulatory resubmission phase
Watch Items
- FDA Resubmission of CTx-1301 NDATrigger: Submission of requested Chemistry, Manufacturing, and Controls (CMC) dataAction: Monitor company announcements and SEC filings for formal resubmission timeline and FDA acceptance
- CDMO Facility Remediation (Form 483 Observations)Trigger: Resolution of the three FDA observations (two facility-related, one CTx-1301 specific)Action: Track progress of Bend Bio Sciences and manufacturing partners in addressing FDA observations
- Capital Runway and Dilution RiskTrigger: Cash reserves falling below $15 millionAction: Evaluate utilization of the AGP/Alliance Global Partners ATM sales agreement and Lincoln Park stock purchase agreement
Research as of 20 Jun 2026